Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Product Type
  5. Other
  6. Medtech Products

Medtech Products

Evaluate

January 23, 2023

A year to forget for medtech stocks

The biggest surprise is that there were a handful of risers despite the widespread market turmoil.

January 13, 2023

Medtech approvals stagnate

Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.

Article image
Vantage logo
January 11, 2023

Few big bangs in a quiet year for medtech mergers

J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.

Article image
Vantage logo
August 09, 2021

Medtronic finally bags Intersect ENT

Article image
Vantage logo
March 04, 2021

Asensus Senhances its offering

Article image
Vantage logo
September 01, 2020

ESC 2020 roundup – Amarin touts plaque data as appeal looms

A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.

Article image
Vantage logo
August 08, 2019

Glaukos eyes growth injection with Avedro buy

Article image
Vantage logo
July 25, 2019

Roche pushes pipeline as US biosimilars hit

Article image
Vantage logo
June 27, 2019

Bracco’s Blue Earth buy boosts Syncona

Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.

Article image
Vantage logo
March 17, 2019

ACC 2019 – Medtronic gets a new box of Tyrx

Article image
Vantage logo
February 13, 2019

J&J’s Auris buy looks like a Verb swerve

Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up